What Positive Phase-I findings Mean For Immunomedics Inc. (NASDAQ:IMMU)?

Posted by Lynn Eisler October 23, 2013 0 Comment 1043 views


Immunomedics, Inc. (NASDAQ:IMMU), primarily engaged in developing monoclonal antibody based targeted therapies for cancer, autoimmune and other serious diseases, announced on Tuesday that its newest ADC (Antibody Drug Conjugate), IMMU132 has demonstrated successful partial responses in three different types of cancers during the early phase of clinical studies.

In Phase I study total of 25 patients were enrolled with 12 different types of epithelial cancers who failed prior standard therapies with a median of 3 in range 1-6.  The drug under trial, IMMU132 was administered weekly consecutively for two week and was followed by one week off in three-week cycles, with treatments planned to remain continue up to 8 cycles.

As far findings are concerned, partial responses were observed in 3 patients by CT (Computed Tomography), stable disease in 15 patients and overall diseases control rate of 86% in around 21 patients with at least one CT assessment. The CT assessment in the study used RECIST criteria. Moreover half of the patients demonstrated CT confirmed tumor shrinkage. The results from this study were presented for the first time after peer-review of the abstract submitted. The study has now moved into Phase II for additional safety and efficacy data.

The results from the Phase I clinical trial which is a multicenter, dose escalation study were presented by Dr. Alexander N. Starodub at the AARC International Conference in Boston. The conference was on Molecular Targets and Cancer Therapeutics.

Alongside Immunomedics,  in other developments against immune-mediated diseases, Bristol-Myers Squibb Co. (NYSE:BMY) yesterday announced acceptance of 20 abstracts which will be presented during October 25-30 at the annual meeting of ACR (American College of Rheumatology) to be hosted in San Diego, CA. The company will present Phase IIb findings of its drug candidate Clazakizumab intended to treat moderate to severe RA (Rheumatoid Arthritis); findings of two year AMPLE trial conducted on biologic-naïve RA patients and over ten health economics and outcomes research presentations that will highlight use of RA medications and costs associated with the treatment.



About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment